Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Surfing the MASH Tsunami
S2-E16.3 - How NASH treatment Might Evolve as Therapies Come to Market
•
HEP Dynamics
•
Season 2
•
Episode 16
The final conversation of Episode 16 explores possible possible pathways and treatment strategies for NASH therapy in a future world with multiple classes of agents.
In different ways, Mazen Noureddin and each Surfer discuss how cost-effective patient treatment might actually provide the right medicine for the right patient all along the therapeutic path.
What makes NASH a little different from other diseases? Because the liver can heal itself, doctors will need to manage drug use during the disease regression process if all goes well.
This is a different way of thinking, driven in part by the ground-breaking cost-effectiveness work Mazen and others have brought forward.
In different ways, Mazen Noureddin and each Surfer discuss how cost-effective patient treatment might actually provide the right medicine for the right patient all along the therapeutic path.
What makes NASH a little different from other diseases? Because the liver can heal itself, doctors will need to manage drug use during the disease regression process if all goes well.
This is a different way of thinking, driven in part by the ground-breaking cost-effectiveness work Mazen and others have brought forward.